Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Bristol Myers Faces Another Trial Disappointment As Heart Drug Milvexian Fails To Show Efficacy

Rueil-malmaison,,France,-,August,13,,2023:,French,Headquarters,Of,Bristol-myers

Bristol Myers Squibb & Co. (NYSE:BMY), in collaboration with Johnson & Johnson (NYSE:JNJ), announced Friday that they decided to stop the Phase 3 Librexia ACS trial evaluating the efficacy and safety of milvexian when added to the standard of care (conventional antiplatelet therapy) for patients after a recent acute coronary syndrome (ACS) event.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.